Business Context and Reporting Period
This Form 8-K, dated June 10, 2014, reports on Camp Nine, Inc. (the registrant, formerly associated with Relmada Therapeutics, Inc. via a reverse merger). The filing details the final closing of a private placement of securities to accredited investors.
Key Financial Metrics and Transaction Details
- Gross Proceeds: The Company received an aggregate of $10,694,588 from the sale of securities.
- Securities Issued:
- 7,129,725 shares of Common Stock.
- Series A Warrants to purchase 7,129,725 shares at an exercise price of $1.50 per share (120-day term).
- Series B Warrants to purchase 3,564,862 shares at an exercise price of $2.25 per share (5-year term).
- Placement Agent Fees: Laidlaw & Company (UK) Ltd. received a cash fee of $1,069,458 (10% of gross proceeds) plus a 2% non-accountable expense fee and warrants to purchase 1,782,431 shares.
- Liquidity and Debt: The filing does not provide specific data on existing debt, operating cash flow, or current liquidity ratios outside of the proceeds from this transaction.
Material Changes and Agreements
The primary material change is the capital raise and the execution of several definitive agreements:
- Investor Rights Agreement: The Company is obligated to file a registration statement for the shares and warrant shares. Failure to file or declare effectiveness within the agreed timeframe triggers a penalty of 1% of the total purchase price per month, capped at 6% in the aggregate.
- Management Lock-Up: Officers and directors agreed not to sell shares for the earlier of 12 months from May 20, 2014, or 6 months following the effective date of the registration statement.
- CEO Lock-Up: The CEO agreed not to sell shares until three months after the Company up-lists to a U.S. national stock exchange (e.g., NASDAQ or NYSE MKT).
Outlook, Risks, and Contingencies
- Registration Risk: The Company faces a financial penalty (up to 6% of the purchase price) if it fails to timely file or declare effective the registration statement for the new securities.
- Listing Contingency: The CEO's ability to sell shares is contingent upon the Company successfully up-listing to a major U.S. exchange.
- Regulatory Status: The securities were sold under Rule 506 of Regulation D and have not been registered under the Securities Act of 1933.
Investor Verification Checklist
- Verify the status of the registration statement required under the Investor Rights Agreement to assess potential penalty liabilities.
- Confirm the Company's progress toward up-listing to a U.S. national stock exchange, as this impacts the CEO lock-up and market liquidity.
- Review the full text of the Unit Purchase Agreement and Warrant forms (Exhibits 10.1, 4.1, 4.2) for specific adjustment provisions and dilution risks.
- Check subsequent filings to confirm the effective date of the registration statement and any payments made to investors for delays.